Register Now
Course Information

Since the first clinical classification of focal cortical dysplasia (FCDs) almost two decades ago, there have been many advances in the recognition and management of this diverse pathology in the setting of pharmacoresistant focal epilepsies. These advances include better understanding of the electro-clinical manifestations of the FCDs, advanced imaging-pathological correlations and new insights on the genetic characterization of these pathologies. The Summit has the esteemed endorsement of the ILAE and our goal is to chart the future of research and management of FCD by bringing together world leaders to discuss the advances they have made in this field, identify challenges and act on the opportunities.

Learning Objectives

After completing this educational activity, participants will be able to do the following:

  • Review the evidence base supporting the revised focal cortical dysplasia (FCD) classification and
    describe its impact on clinical practice.
  • List the challenges of FCD classification from a pathological standpoint and highlight the role
    of molecular/genetics/imaging findings in addressing the current shortcomings in the current
    classification.
  • Discuss the role of genetics in the FCD classification update.
  • Address the clinical implications of FCD classification on epilepsy treatment, both medical and
    surgical.

Target audience

Adult and Pediatric Neurologists, Neurosurgeons, Epilepsy Fellows, Residents in Adult and Pediatric Neurology, Neuroscientists, Molecular Biologists, Pathologists, Pharmacists and Geneticists